ducovest

IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 59.31

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.31M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

N/A

 USD 37.80B
FHLC Fidelity® MSCI Health Care In..

N/A

 USD 2.66B
FXH First Trust Health Care AlphaD..

N/A

 USD 1.07B
XHE SPDR® S&P Health Care Equipme..

N/A

 USD 0.21B
IDNA iShares Genomics Immunology an..

N/A

 USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

N/A

 USD 0.09B
XHS SPDR® S&P Health Care Service..

N/A

 USD 0.07B
HTEC Robo Global® Healthcare Techn..

N/A

 USD 0.05B
BBP Virtus LifeSci Biotech Product..

N/A

 USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

N/A

 USD 8.55M

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

N/A

 N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.78% 50% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.78% 50% F 55% F
Trailing 12 Months  
Capital Gain 1.41% 48% F 38% F
Dividend Return 1.24% 81% B- 20% F
Total Return 2.65% 48% F 27% F
Trailing 5 Years  
Capital Gain 34.03% 86% B+ 67% D+
Dividend Return 7.15% 74% C 20% F
Total Return 41.18% 95% A 63% D
Average Annual (5 Year Horizon)  
Capital Gain 6.25% 71% C- 55% F
Dividend Return 7.25% 76% C+ 51% F
Total Return 1.01% 79% B- 25% F
Risk Return Profile  
Volatility (Standard Deviation) 18.50% 57% F 59% D-
Risk Adjusted Return 39.21% 71% C- 53% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike